The Korea Medical Institute (KMI) announced on Tuesday a strategic partnership with Guardant Health, a US-based company, to advance precision cancer screening through liquid biopsy technology.
The memorandum of understanding (MOU) was officially signed on March 5th at the KMI Foundation headquarters in Seoul. Key figures present included KMI Chairman Lee Kwang-bae, KMI Strategic Planning Office Head Lee Kwang-yup, Guardant Health AMEA Vice President Divya Mehta, and Guardant Health Korea Country Manager Michael Jung.
This collaboration will focus on providing cutting-edge precision oncology services, utilizing liquid biopsy for early cancer detection and comprehensive genomic mutation analysis. The two organizations are also committed to developing an integrated cancer management system. This system will combine advanced screening services with expert consultations from medical professionals and seamless referral pathways to university hospitals for further diagnosis and tailored treatment plans.
The partnership aims to progressively enhance the precision genomic analysis capabilities of both KMI and Guardant Health.
“Liquid biopsy-based precision diagnostics represent a significant breakthrough in medical science, offering the potential for earlier cancer detection and more personalized treatment strategies,” stated Lee Kwang-bae, Chairman of KMI.
“Through this strategic alliance, we are dedicated to delivering more accurate and effective cancer screening services, ultimately contributing to the advancement of precision medicine in Korea,” Lee added.
KMI, established in 1985, operates a network of eight comprehensive health screening centers across South Korea. These centers are located in major cities, including three in Seoul (Gwanghwamun, Yeouido, and Gangnam), as well as Suwon, Daegu, Busan, Gwangju, and Jeju Island.
stlee0329
